These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15184306)

  • 1. From bench to bedside and back again?
    CMAJ; 2004 Jun; 170(12):1765, 1767. PubMed ID: 15184306
    [No Abstract]   [Full Text] [Related]  

  • 2. Gefitinib: phoenix from the flames.
    Lancet Oncol; 2009 Aug; 10(8):737. PubMed ID: 19647191
    [No Abstract]   [Full Text] [Related]  

  • 3. EGFR mutations and sensitivity to gefitinib.
    Sorscher SM
    N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15371587
    [No Abstract]   [Full Text] [Related]  

  • 4. Gefitinib. Still no convincing results in non-small cell lung cancer.
    Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
    [No Abstract]   [Full Text] [Related]  

  • 5. Gefitinib does not increase survival in lung cancer patients.
    Golsteyn RM
    Drug Discov Today; 2005 Mar; 10(6):381. PubMed ID: 15808815
    [No Abstract]   [Full Text] [Related]  

  • 6. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
    Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
    [No Abstract]   [Full Text] [Related]  

  • 7. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
    [No Abstract]   [Full Text] [Related]  

  • 8. Interstitial lung disease and gefitinib.
    Lim KH; Chang YH
    N Engl J Med; 2010 Oct; 363(16):1579; author reply 1579-80. PubMed ID: 20949670
    [No Abstract]   [Full Text] [Related]  

  • 9. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE; Ramalingam SS
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract]   [Full Text] [Related]  

  • 10. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Costa DB; Kobayashi S
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
    [No Abstract]   [Full Text] [Related]  

  • 11. Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction.
    Jänne PA
    J Clin Oncol; 2006 Jul; 24(21):3319-21. PubMed ID: 16785470
    [No Abstract]   [Full Text] [Related]  

  • 12. EGFR mutations and sensitivity to gefitinib.
    Rossi G; Marchioni A; Longo L
    N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15376351
    [No Abstract]   [Full Text] [Related]  

  • 13. Approved use of gefitinib.
    Lyle J
    Am J Health Syst Pharm; 2004 Oct; 61(19):2008; author reply 2008. PubMed ID: 15509120
    [No Abstract]   [Full Text] [Related]  

  • 14. More haste, less speed.
    Lancet Oncol; 2003 Jun; 4(6):325. PubMed ID: 12788389
    [No Abstract]   [Full Text] [Related]  

  • 15. Interstitial lung disease and gefitinib.
    Murashige N; Tanimoto T; Oshima Y
    N Engl J Med; 2010 Oct; 363(16):1578-9; author reply 1579-80. PubMed ID: 20942679
    [No Abstract]   [Full Text] [Related]  

  • 16. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
    Shih JY; Gow CH; Yang PC
    N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
    [No Abstract]   [Full Text] [Related]  

  • 17. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
    Viswanathan A; Pillot G; Govindan R
    Lung Cancer; 2005 Dec; 50(3):417-8. PubMed ID: 16129510
    [No Abstract]   [Full Text] [Related]  

  • 18. EGFR mutation and response of lung cancer to gefitinib.
    Toyooka S; Kiura K; Mitsudomi T
    N Engl J Med; 2005 May; 352(20):2136; author reply 2136. PubMed ID: 15901872
    [No Abstract]   [Full Text] [Related]  

  • 19. The TAILOR study: to agree or to disagree?
    Moro-Sibilot D; Perol D; Chabaud S; Cadranel J; Audigier Valette C; Perol M
    Lung Cancer; 2014 Jun; 84(3):315-6. PubMed ID: 24751106
    [No Abstract]   [Full Text] [Related]  

  • 20. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
    Cho D; Kocher O; Lee JC; Tenen DG; Meyerson ML; Janne PA; Halmos B
    J Clin Oncol; 2005 Jan; 23(1):235-7. PubMed ID: 15625379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.